Table 2. Association of LPAAT-β expression and various clinicopathological factors.
| Characteristic | All cases | LPAAT-β-negative | LPAAT-β-positive | P-value |
|---|---|---|---|---|
| Histological type | 64 (100%) | 25 (39%) | 39 (61%) | |
| Differentiated | ||||
| Undifferentiated | 12 (100%) | 1 (8%) | 11 (92%) | 0.049a |
| Histological grade (Silverberg) | ||||
| G1–2 | 49 (100%) | 21 (43%) | 28 (57%) | |
| G3 | 27 (100%) | 5 (19%) | 22 (81%) | 0.044a |
| PT | ||||
| pT1 | 15 (100%) | 9 (60%) | 6 (40%) | |
| pT2–3 | 61 (100%) | 17 (28%) | 44 (72%) | 0.032a |
| PN | ||||
| pN0 | 25 (100%) | 9 (36%) | 16 (64%) | |
| pN1 | 21 (100%) | 7 (33%) | 14 (67%) | 1.0a |
| PM | ||||
| PMX | 72 (100%) | 24 (33%) | 48 (67%) | |
| pM1 | 4 (100%) | 2 (50%) | 2 (50%) | 0.6a |
| FIGO stage | ||||
| I | 16 (100%) | 8 (50%) | 8 (50%) | |
| II | 11 (100%) | 2 (18%) | 9 (82%) | |
| III | 45 (100%) | 14 (31%) | 31 (69%) | |
| IV | 4 (100%) | 2 (50%) | 2 (50%) | 0.47b |
| Residual tumour | ||||
| < 2 cm | 26 (100%) | 9 (35%) | 17 (65%) | |
| >2 cm | 6 (100%) | 1 (17%) | 5 (83%) | 0.64a |
| Chemotherapy | ||||
| Platinum-based CTX | 44 (100%) | 16 (36%) | 28 (64%) | |
| Other CTX | 4 (100%) | 1 (25%) | 3 (75%) | |
| No CTX | 7 (100%) | 4 (57%) | 3 (43%) | 0.4c |
| Age at surgery (years) | ||||
| <60 | 45 (100%) | 17 (38%) | 28 (62%) | |
| >60 | 31 (100%) | 9 (29%) | 22 (71%) | 0.47a |
a
Fisher's exact test, two-sided.
b
χ2 for trends.
c
Pearson's χ2, two-sided.